Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$5.10
-$0.11(-3.08%)
At close: 4:00 PM EST
$5.10
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$2.37 - $7.11
Previous CloseN/A
Volume131.37K
Average Volume (3M)2.38M
Market Cap
$643.67M
Enterprise Value$142.63
Total Cash (Recent Filing)$29.27M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Aug 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding102,659,060
10 Day Avg. Volume1,711,009
30 Day Avg. Volume2,375,488
Financial Highlights & Ratios
PEG Ratio-4.93
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.33Price Target Upside181.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase III Clinical EfficacyRobust, reproducible Phase III efficacy—especially in previously treated, hard-to-treat subgroups—creates a durable clinical differentiation that supports formulary access, physician adoption, and commercial uptake. Strong clinical effect sizes reduce reliance on adjunct therapies and strengthen long-term market penetration and payer negotiations.
Transformational Financing And CapitalizationA large upfront financing materially extends runway through regulatory resubmission, planned vaping Phase III initiation, and commercial build-out costs. This reduces immediate dilution risk from emergency financings, enables execution of strategic milestones, and increases probability of reaching a revenue-generating launch window.
Intellectual Property ProtectionLong-dated IP protection provides a durable commercial franchise enabling multi-year pricing, return on launch investments, and competitive barriers. Extended exclusivity supports partner interest, justifies upfront commercialization spending, and can underpin sustained revenue once approved and adopted by prescribers and payers.
Bears Say
No Revenue And Persistent Net LossesA pre-commercial profile with sustained large net losses means the company must rely on external capital until product approval and launch. This structural lack of revenue constrains reinvestment, increases sensitivity to financing conditions, and risks shareholder dilution if execution or approval timelines slip.
Heavy Cash Burn And Negative Cash FlowPersistent negative operating and free cash flow translates losses into real cash depletion, creating ongoing need for capital and limiting strategic flexibility. Even with recent financing, sustained burn raises the chance of future financings, constrains commercial investment sizing, and increases execution risk if milestones are delayed.
Regulatory CRL And Manufacturing Execution RiskAn expected FDA complete response tied to a third-party OAI forces an NDA resubmission and onshore tech transfer to a new manufacturer. That creates multi-quarter to multi-year timing uncertainty, raises the risk of additional regulatory queries, and places material execution risk on manufacturing scale-up ahead of a planned commercial launch.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.37 and its highest was $7.11 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $643.67M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on May 12, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.109.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.16.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,659,060 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went up 7.156%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (181.05% Upside)
$14.33 (181.05% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.01%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
ACHV Stock 12 Month Forecast
Average Price Target
$14.33
▲(181.05% Upside)
Technical Analysis
Ownership Overview
0.87% Insiders
4.25% Mutual Funds
1.54% Other Institutional Investors
82.33% Public Companies and
Individual Investors